( EO commented I amdelighted to report ...)Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials,Health

EO commented "I am delighted to report such positive results, which confirm the therapeutic and commercial potential of ACE393. This important outcome for ACE BioSciences validates our approach and preclinical work and keeps us on track to launch ACE393 in 2010. In September last year, we entered a collaborative development agreement with the US Naval Medical Research Center (NMRC) to progress ACE393 through Phase II clinical trials and we are about to initiate the first of these studies. These are exciting times for ACE BioSciences in a transformational year for the company."

72 healthy subjects participated in the trial which was undertaken at the Mediscis Phase I clinical unit in Poitiers, France. ACE BioSciences will continue to monitor those patients who received the vaccine at three monthly intervals to evaluate the longevity of the immune response. The full results of the study will be presented by Dr Michael Darsley, Chief Development Officer at ACE BioSciences at the Vaccines for Enteric Diseases Conference, held in Portugal on 25-27 April 2007.

TD is the most frequent health problem in travellers from industrialized countries visiting developing countries. Recent research undertaken by Beremans Ltd in the US and UK, indicates that an effective Campylobacter vaccine for Traveller's Diarrhoea might be purchased by over two million travellers per year and ACE BioSciences estimates that this annual global market would be worth _350 million. The company aims to claim a substantial share of the market by providing the first effective commercial Campylobacter vaccine that delivers good protection and low side effect risk.

Notes for Editors

About Travellers Diarrhoea

Campylobacter jejuni is a bacterium that is one of the main causes of travellers_ diarrhoea. In addition to the disruption it causes to business and holiday travellers, infection is a significant issue for the military and among the 140,000 US military perso
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy